ImmCelz Inc

Creative Medical Technology Holdings, Inc., based in Phoenix, AZ, is a biotechnology company dedicated to enhancing patient outcomes through innovative regenerative medicine and immunotherapy solutions. With a strong focus on developing unique platforms such as ImmCelz, the firm aims to advance treatments for various medical conditions including immunology, endocrinology, urogynecology, and orthopedics. Backed by an experienced management team and a substantial intellectual property portfolio, Creative Medical Technology Holdings is committed to creating disruptive technologies that address sizable market needs. The company is actively engaged in clinical trials to further its mission of improving patient lives through advancements in regenerative medicine. Generated from the website

Gox Labs is a Phoenix, Arizona-based company that specializes in innovative solutions for workforce safety and virtual cardiac rehabilitation. The organization focuses on delivering tailored services for government use cases, enhancing health and safety through advanced technology. Committed to providing comprehensive support, Gox Labs offers a variety of resources, including case studies and validation data, to assist clients in understanding their products and services. The company emphasizes a collaborative approach by allowing customers to connect and request additional information on relevant topics. Generated from the website

nVector's next-generation gene therapy technology is poised to enable revolutionary treatments for central nervous systems (CNS) diseases such as Alzheimer's, Parkinson's, ALS, and traumatic brain injury. To drive this capability, the company has brought on board Fredric Manfredsson, Ph.D. as Chief Scientific Officer to team with Robert Bowser, Ph.D., nVector's Chairman of the Board. Together they are directing the development of nVector's Adeno-Associated Virus platform, which features the first technology to target brain glia (immune) and neuron cells by type and offers better distribution throughout the spinal cord and brain from a single injection. The combination of nVector's AAV platform and biomarker assays, including the first biologic diagnostic test for ALS, differentiates nVector from other biotechnology companies in the space.